Can change in high-density lipoprotein cholesterol levels reduce cardiovascular risk?

American Heart Journal

Volumn 147, Issue 6, 2004, Pages 966-976

  Dean, Bonnie B ^a   Borenstein, Jeff E ^a,b   Henning, James M ^c   Knight, Kevin ^a   Merz, C Noel Bairey ^d  

^a Zynx Health   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c TAP PHARMACEUTICAL PRODUCTS INC   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; COLESTIPOL; ESTROGEN; FATTY ACID; FIBRIC ACID DERIVATIVE; FISH OIL; GEMFIBROZIL; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSAPENTAENOIC ACID; LINOLEIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; RESIN; STATIN;

ATHEROSCLEROSIS; CALCULATION; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DRUG EFFECT; DYSLIPIDEMIA; HEART INFARCTION; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; LOGISTIC REGRESSION ANALYSIS; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW;

EID: 3042851669     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2003.10.051     Document Type: Article

References (54)

1. Castelli W.P., Garrison R.J., Wilson P.W., et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA. 256:1986;2835-2838
2. Stamler J., Wentworth D., Neaton J.D. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356, 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 256:1986;2823-2828
3. Wilson P.W., Anderson K.M., Castelli W.P. Twelve-year incidence of coronary heart disease in middle-aged adults during the era of hypertensive therapy the Framingham offspring study. Am J Med. 90:1991;11-16
4. Frick M.H., Elo O., Haapa K., et al. Helsinki Heart Study primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 317:1987;1237-1245
5. Gordon D.J., Knoke J., Probstfield J.L., et al. High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men the Lipid Research Clinics Coronary Primary Prevention Trial. Circulation. 74:1986;1217-1225
6. Wilson P.W., Abbott R.D., Castelli W.P. High-density lipoprotein cholesterol and mortality the Framingham Heart Study. Arteriosclerosis. 8:1988;737-741
7. Thompson G.R., Hollyer J., Waters D.D. Percentage change rather than plasma level of LDL-cholesterol determines therapeutic response in coronary heart disease. Curr Opin Lipidol. 6:1995;386-388
8. Jukema J.W., Bruschke A.V., van Boven A.J., et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels the Regression Growth Evaluation Statin Study (REGRESS). Circulation. 91:1995;2528-2540
9. Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet. 345:1995;1274-1275
10. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998;97:1440-5
11. Sacks F.M., Gibson C.M., Rosner B., et al. The influence of pretreatment low density lipoprotein cholesterol concentrations on the effect of hypocholesterolemic therapy on coronary atherosclerosis in angiographic trials. Harvard Atherosclerosis Reversibility Project Research Group. Am J Cardiol. 76:1995;78-85C
12. Shah P.K., Kaul S., Nilsson J., et al. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins an idea whose time for testing is coming, part I. Circulation. 104:2001;2376-2383
13. Shah P.K., Kaul S., Nilsson J., et al. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins an idea whose time for testing is coming, part II. Circulation. 104:2001;2498-2502
14. Robins S.J., Collins D., Wittes J.T., et al. Relation of gemfibrozil treatment and lipid levels with major coronary events VA-HIT: a randomized controlled trial. JAMA. 285:2001;1585-1591
15. Cheung M.C., Zhao X.Q., Chait A., et al. Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL. Arterioscler Thromb Vasc Biol. 21:2001;1320-1326
16. Brown B.G., Zhao X.Q., Chait A., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 345:2001;1583-1592
17. Knuiman M.W., Vu H.T. Prediction of coronary heart disease mortality in Busselton, Western Australia an evaluation of the Framingham, national health epidemiologic follow up study, and WHO ERICA risk scores. J Epidemiol Community Health. 51:1997;515-519
18. Dobson A.J., Evans A., Ferrario M., et al. Changes in estimated coronary risk in the 1980s data from 38 populations in the WHO MONICA Project. World Health Organization. Monitoring trends and determinants in cardiovascular diseases. Ann Med. 30:1998;199-205
19. Waters D., Higginson L., Gladstone P., et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation. 89:1994;959-968
20. Brensike J.F., Levy R.I., Kelsey S.F., et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis results of the NHLBI Type II Coronary Intervention Study. Circulation. 69:1984;313-324
21. Tamura A., Mikuriya Y., Nasu M. Effect of pravastatin (10 mg/day) on progression of coronary atherosclerosis in patients with serum total cholesterol levels from 160 to 220 mg/dl and angiographically documented coronary artery disease. Coronary Artery Regression Study (CARS) Group. Am J Cardiol. 79:1997;893-896
22. Teo K.K., Burton J.R., Buller C.E., et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis the Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). Circulation. 102:2000;1748-1754
23. von Schacky C., Angerer P., Kothny W., et al. The effect of dietary omega-3 fatty acids on coronary atherosclerosis a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 130:1999;554-562
24. Sacks F.M., Pasternak R.C., Gibson C.M., et al. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group. Lancet. 344:1994;1182-1186
25. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994;344:633-8
26. Sacks F.M., Stone P.H., Gibson C.M., et al. Controlled trial of fish oil for regression of human coronary atherosclerosis. HARP Research group. J Am Coll Cardiol. 25:1995;1492-1498
27. White H.D., Simes R.J., Anderson N.E., et al. Pravastatin therapy and the risk of stroke. N Engl J Med. 343:2000;317-326
28. Elkeles R.S., Diamond J.R., Poulter C., et al. Cardiovascular outcomes in type 2 diabetes a double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care. 21:1998;641-648
29. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9
30. Herd J.A., Ballantyne C.M., Farmer J.A., et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study. [LCAS]) Am J Cardiol. 80:1997;278-286
31. Blankenhorn D.H., Azen S.P., Kramsch D.M., et al. Coronary angiographic changes with lovastatin therapy the Monitored Atherosclerosis Regression Study (MARS). The MARS Research Group. Ann Intern Med. 119:1993;969-976
32. Furberg C.D., Adams H.P. Jr, Applegate W.B., et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research group. Circulation. 90:1994;1679-1687
33. Mercuri M., Bond M.G., Sirtori C.R., et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population the Carotid Atherosclerosis Italian Ultrasound Study. Am J Med. 101:1996;627-634
34. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000;102:21-7
35. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Am J Cardiol 1993;72:1031-7
36. Pitt B., Mancini G.B., Ellis S.G., et al. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I) reduction in atherosclerosis progression and clinical events. PLAC I investigation. J Am Coll Cardiol. 26:1995;1133-1139
37. Singh R.B., Niaz M.A., Sharma J.P., et al. Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction the Indian experiment of infarct survival-4. Cardiovasc Drugs Ther. 11:1997;485-491
38. Byington R.P., Furberg C.D., Crouse J.R. III, et al. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol. 76:1995;54-59C
39. Gundersen T., Kjekshus J., Stokke O., et al. Timolol maleate and HDL cholesterol after myocardial infarction. Eur Heart J. 6:1985;840-844
40. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) research group. JAMA. 280:1998;605-613
41. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 335:1996;1001-1009
42. Frick M.H., Syvanne M., Nieminen M.S., et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterolLopid Coronary Angiography Trial (LOCAT) Study group. Circulation. 96:1997;2137-2143
43. Ericsson C.G., Hamsten A., Nilsson J., et al. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet. 347:1996;849-853
44. Brown G., Albers J.J., Fisher L.D., et al. Regression of coronary artery disease as a result of intensive lipid- lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 323:1990;1289-1298
45. Rubins H.B., Robins S.J., Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study group. N Engl J Med. 341:1999;410-418
46. Bestehorn H.P., Rensing U.F., Roskamm H., et al. The effect of simvastatin on progression of coronary artery disease. The Multicenter coronary Intervention Study (CIS). Eur Heart J. 18:1997;226-234
47. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251:365-74
48. Blankenhorn D.H., Nessim S.A., Johnson R.L., et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 257:1987;3233-3240
49. Salonen R., Nyyssonen K., Porkkala E., et al. Kuopio Atherosclerosis Prevention Study (KAPS) a population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation. 92:1995;1758-1764
50. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study group. N Engl J Med. 333:1995;1301-1307
51. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 279:1998;1615-1622
52. Liao Y., McGee D.L., Cooper R.S., et al. How generalizable are coronary risk prediction models? Comparison of Framingham and two national cohorts. Am Heart J. 137:1999;837-845
53. Ballantyne C.M., Olsson A.G., Cook T.J., et al. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation. 104:2001;3046-3051
54. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97